AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...
Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.
A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.
Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...
With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).
The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...
Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if ...
Nabla Bio has entered a new multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics ...
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...
A spike in licensing of candidates developed in China this year is a sign of the country’s transition in the global pharma ...
Goldman Sachs has secured the top spot as the leading financial adviser in mergers and acquisitions (M&A) based on deal value ...